Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
University of Pittsburgh
Merck Sharp & Dohme LLC
TransThera Sciences (Nanjing), Inc.
Symphogen A/S
TransThera Sciences (Nanjing), Inc.
Celldex Therapeutics
NextCure, Inc.
Klus Pharma Inc.
Tempest Therapeutics
Xencor, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
AbbVie
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins